Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/j7998668

ADVANCES IN HYPERTENSION: A COMPREHENSIVE REVIEW OF CURRENT RESEARCH AND TREATMENT APPROACHES

Jay Patel*, Dr. Nishkruti Mehta[1], Dr. Pragnesh Patani[2]

*Khyati College of Pharmacy, Palodia, Ahmedabad
[1]Associate Professor, Head of the Pharmacology department, Khyati College of Pharmacy, Palodia, Ahmedabad
[2]Principal, Khyati College of Pharmacy, Palodia, Ahmedabad

***Corresponding Author:** Jay Patel
*Khyati College of Pharmacy, Palodia, Ahmedabad, Email: pateljay112003@gmail.com

Abstract:
Hypertension has an impact on people's everyday lives and is a chronic condition that is the leading cause of death and morbidity globally, as well as a substantial risk factor for heart disease, renal disease, and cerebrovascular illness. It also has a negative influence on life quality. According to WHO, hypertension is a significant cause of mortality in high-income countries, where it is still mostly underdiagnosed and undertreated. Hypertension is currently having a rising impact, particularly in low-income countries. Tentatively, 24% of men and 23% of women in the 20-70-year-old adult population had hypertension, which is assessed on the basis of reading higher than or equal to 140/90 mm Hg people are now taking antihypertensive drugs, either in combination probability being single throughout the conditional period. Over the last two decades, research on the genetics and pharmacogenomics of primary hypertension has yielded intriguing findings that point to the relevance of genetics, but no precise information that can be utilized to modify treatment. Traditional drugs used to treat hypertension include ACE inhibitors, calcium channel blockers, beta blockers, and renin inhibitors. There are several studies accessible, as well as ongoing research on hypertension treatment. A new medicine may greatly improve on presently available hypertension therapies, although it cannot cure hypertension entirely.All we can do is lower the risk factor by adjusting our eating and living habits. The current assessment focuses on how new technology and dedicational improvements might aid in the diagnosis and treatment of hypertension.

Keywords: Hypertension, Inhibitors, Self-medication, Self-treatment

Introduction: (1-9)

Hypertension, marked by consistently high blood pressure, continues to be a major global health issue, significantly contributing to the rising incidence of cardiovascular diseases and related health complications.(1) Despite advancements in treatment options, effectively managing hypertension remains a significant challenge for healthcare professionals around the world. In light of this, a thorough understanding of hypertension management strategies is essential.(2) This article offers an in-depth review of the current state of hypertension management, integrating evidence-based clinical guidelines, patient-centered care approaches, and the latest therapeutic developments. By combining clinical evidence with real-world case studies and addressing health disparities, this review seeks to

provide practical insights and recommendations for enhancing hypertension care and improving patient outcomes.[3]

The global population of older adults is increasing at a quicker pace than the general population, leading to a significant rise in both hypertension and cardiovascular risk associated with aging.[4,5,6]

Increase in Numbers of Older Adults and Impact On the Global Burden of Hypertension and Cardiovascular Disease : [7-9]

The number of adults aged 60–79 years is projected to increase from 760 million in 2015 to 1.646 billion by 2050, growing from 10.4% to 17.0% of the global population (Fig. 1, top).[7] The population of adults aged 80 and older is expected to increase from 126.6 million in 2015 to 430.3 million by 2050, rising from 1.7% to 4.4% of the global population (Fig. 1, middle). Projected Increase in Older Adults with Hypertension: If approximately 65% of adults aged 60–79 years and 80% of adults aged 80 and older have hypertension, defined by blood pressure ≥ 140/90 mmHg or the use of antihypertensive medication, then the number of adults aged 60–79 with hypertension is expected to rise from about 494 million in 2015 to 1.07 billion by 2050. Simultaneously, the number of adults aged 80 and older with hypertension could increase from 101 million in 2015 to 344 million by 2050 (Fig. 1, bottom). As a result, by 2050, the number of older adults with hypertension will surpass the total number of adults aged 30–79 with hypertension globally in 2010.[8] The growing number of older adults is significantly contributing to the global burden of hypertension and cardiovascular disease. Advances in understanding and managing hypertension have become increasingly critical as the aging population expands, exacerbating the global burden of hypertension and cardiovascular disease.

Demographic Shift:

The proportion of older adults in the global population is rising due to increased life expectancy and declining birth rates. By 2050, it is estimated that one in six people worldwide will be over the age of 65, with the most significant growth occurring in low- and middle-income countries.

Cardiovascular Disease Burden:

Cardiovascular diseases, including heart disease and stroke, are the leading causes of death globally. Aging is a primary risk factor for these diseases, meaning that the growing older population will likely lead to an increase in CVD incidence, morbidity, and mortality.



Fig. 1 The numbers and percentages of adults 60–79 and ≥ 80 years globally in 2015 and 2050.
Legend. The global numbers of adults 60–79 and ≥80 years in 2015 and 2050 (top panel), respective percentages of the total global population (middle panel), and numbers with hypertension (bottom panel) are shown. The projected increases are large and have important implications for the global health and economic burden of hypertension and related cardiovascular disease.[9]

Digital/Health Technology for Diagnosis and Monitoring [10-17]

As digital/health technology improves, the commercialization of electronic devices for remote blood pressure measurement and transmission is increasing. Theoretically, these technologies have the potential to enhance hypertension diagnosis and population-level blood pressure regulation. To draw a connection with diabetes, Dzauno highlighted in his assessment that there were around 1800 applications for diabetes management in 2016, with an excellent growth in digital diabetes marketing [10]. There is no reason why this growth should not extend to the hypertension area in the near future, however the rise of devices and applications for hypertension appears to be considerably slower than that of diabetes control [11].

Unfortunately, not all blood pressure monitoring devices on the market have been verified in accordance with existing recommendations [12,13], and some of them have limits and inadequacies [11]. Particular emphasis is being paid to cuff-less continuous BP monitoring devices as an alternative to existing cuff-based methods, albeit their validity and reliability are still being investigated [11, 15-17]. We believe that some steps are critical to make anewsystem reliable:

1. The system should be easy to wear, inexpensive, and non-intrusive. Systems featured in typical smartwatches would be nice.
2. The system should be tested for accuracy at independent academic or medical facilities. It should allow continuous or almost-continuous blood pressure sensing over lengthy periods of time, months or even years;
3. The system should be connected to an easy-to-use secured digital repository, with software that allows for quick BP retrieval over varied periods of time for computation of relevant statistical measures (BP averages, variability, etc.) and related visuals.
4. The system should be freely available to clinicians, allowing for immediate patient checks and responses, as well as the proposal of adjustments in drug therapy or other measures.
5. Clinical research should rapidly establish blood pressure parameters that can be retrieved from the system and are more suited for predicting organ damage and, hopefully, prognosis. In other words, research should determine which BP readings obtained by the system are most significant for therapeutic considerations.

It is hoped that applying artificial intelligence to these databases, which are expected to contain a wide range of biological data for each patient, will assist doctors and patients in identifying better hypertension control strategies, potentially in conjunction with strategies promoting a healthier diet, increased physical activity, and more intelligent drug use. The expanding use of 'tele-medicine' during the present COVID epidemic should be expanded to include hypertension treatment. However, there is a long way to go.

Digital Sphygmomanometers: Modern digital blood pressure cuffs are easy to use and often connect to smartphone apps, allowing for the storage and tracking of blood pressure readings over time.

Recent Innovations in Hypertension Drug [18-24]

Drug Name – Aprocitentan (Tryvio)

Hypertension affects about 1.28 billion individuals aged 30-79 years globally.[18] Hypertension is a leading cause of early mortality globally.

Controlling high blood pressure (BP) should be part of a complete cardiovascular risk management strategy that includes proper lipid control, diabetes management, antithrombotic treatment, smoking cessation, exercise, and salt restriction. [19]

Lowering high blood pressure decreases the risk of both fatal and nonfatal cardiovascular events, including strokes and myocardial infarctions.[20] These advantages have been seen in controlled studies of antihypertensive medications from a wide range of pharmacologic classes.

A patient is considered resistant hypertensive if their blood pressure consistently exceeds the goal level despite the simultaneous administration of three antihypertensive medications from different classes.[21] These usually include a long-acting calcium channel blocker, a renin-angiotensin aldosterone system inhibitor, and a diuretic. Each agent must be provided at its maximum- or maximum tolerable dose, in accordance with the specified dosing frequency.

Pharmacokinetics:

Absorption - The absolute oral bioavailability of Aprocitentan is unknown. The mean Cmax and AUC0-tau following a single oral dose of 25 mg are approximately 1.3 µg/mL and 23 mcg h/mL, respectively, with a Tmax between and 5 h.

Protein binding - Aprocitentan is highly protein-bound in plasma, primarily to albumin (>99%).
Metabolism - Aprocitentan is primarily metabolized by UGT1A1- and UGT2B7-mediated N-glucosidation and non-enzymatic hydrolysis.
Route of elimination - Following the administration of a single radiolabeled dose of Aprocitentan, approximately 52% of the dose was 84 eliminated via urine (0.2% unchanged) and 25% via feces (6.8% unchanged).[22]

Mechanism of Action
Endothelin-1 (ET-1) is the predominant endothelin isoform in the cardiovascular system. It is produced constitutively by vascular endothelial cells to maintain vascular tone and is found in a variety other cells, including vascular smooth muscle cells, cardiomyocytes, fibroblasts, macrophages, neurons, and epithelial cells in the lungs and kidneys.[23]



Thomas: Aprocitentan (Tryvio)
ET-1 acts on two receptors, ETA and ETB, located on vascular smooth muscle cells and endothelialcells, respectively, which serve to regulate blood pressure by inducing vasoconstriction or vasodilation. ET-1 is an extremely potent vasoconstrictor that primarily interacts with the ETA receptor and, under pathologic conditions, can further induce vasoconstriction via interactions with ETB2. The dual endothelin receptor antagonist Aprocitentan inhibits the binding of ET-1 to both ETA and ETB receptors. This inhibition mitigates the hypertensive effects of ET-1 overexpression, including endothelial dysfunction, vascular hypertrophy and remodeling, sympathetic activation, and increased aldosterone synthesis.

Half-life
The half-life of Aprocitentan is approximately 41 h.

Clearance
The apparent clearance is approximately 0.3 L/h.

Dosage forms and Strengths
Aprocitentan tablets are available as 12.5 mg: yellow to orange round, film-coated tablet.

Pregnancy testing in females of reproductive potential
Initiate treatment with Aprocitentan in females of reproductive potential only after confirmation of a negative pregnancy test. Patients should undergo monthly pregnancy tests during treatment and one month after discontinuation of treatment with Aprocitentan.[24]

SR. NO	NAME OF DRUG	CLASS OF DRUG	ACTIVITY OF DRUG
1	Firibastat (QGC001)	Aminopeptidase A inhibitor.	Firibastat is a first-in-class prodrug that targets the brain renin-angiotensin system (RAS).[25] Its primary action involves inhibiting aminopeptidase A, an enzyme responsible for the conversion of angiotensin II to angiotensin III in the brain.[26] By inhibiting this enzyme, firibastat reduces the levels of angiotensin III, a peptide that plays a crucial role in central blood pressure regulation. Angiotensin III typically increases blood pressure by stimulating the release of vasopressin and activating sympathetic outflow, which leads to vasoconstriction.[27] Firibastat crosses the blood-brain barrier, allowing it to exert its effects directly within the brain. The reduction in angiotensin III levels leads to decreased vasopressin release and sympathetic nervous system activity, resulting in lowered blood pressure.[28] Its selective inhibition of aminopeptidase A and its brain-targeted action make firibastat particularly useful for patients with resistant hypertension, where other peripheral-acting antihypertensive drugs may be less effective.[29]
2	Amlodipine/Olmesartan Medoxomil(k-health)	calcium channel blocker	This combination pill pairs a calcium channel blocker (amlodipine) with an angiotensin II receptor blocker (ARB) (olmesartan) to manage hypertension.[30]
3	Vericiguat (Verquvo)	soluble guanylate cyclase (sgc) stimulators	Vericiguat (Verquvo) is a targeted therapy for heart failure that works by enhancing the natural vasodilation pathways and protecting the heart from further damage.[31] It is particularly beneficial in patients who have recently experienced a worsening of their heart failure symptoms.[32]

Recent Drugs for Hypertension.[25-32]
DEVELOPMENT IN THE TREATEMENT OF HYPERTENSION[33-52]
Vasopeptidases inhibitors :-
Along with Pro, additional metallopeptidases that convert vasoactive chemicals include ACE2, NEP, and endothelin-changing over catalyst (ECE-1). Late findings indicate an incredible potential for consolidated Pro/ECE inhibitors, [33] although the majority of research has been focused on the role of NEP and the therapeutic potential of its inhibition. Nonpartisan endopeptidase substrates have a role with vasodilators as well as vasoconstrictors, and the influence of NEP inhibition on BP is therefore unusually subtle and varied. However, the influence of reduced corruption of vasodilative chemicals following NEP hindrance may win in settings when the production or activity of vasoconstrictors is currently inhibited. Furthermore, the design of molecules impeding both Pro and NEP is very feasible. One of the most anticipated vasopeptidase inhibitors, omapatrilat, decreased BP in a few models of exploratory hypertension[34] and hypertensive subjects compared to sampatrilat. The preliminary OCTAVE and Suggestion studies confirmed the benefit of ACE/NEP inhibitors in

hypertension and cardiovascular breakdown, but they also revealed a greater incidence of angioedema in patients on double constraint.[35] The most likely explanation is the combined action of both vasopeptidases on bradykinin corruption. As a result, the combined AT1R/NEP threat (angiotensin receptor and neprilysin inhibitors, ARNI) may have a higher resilience profile. To be sure, LCZ696, a first-in-class ARNI, lowered BP furthermore with the influence of valsartan, without being associated to the event of angioedema in a Stage II concentration in mild to moderate hypertensive individuals.[36] Furthermore, ARNIs promote increased natriuretic peptide fixation. In primates, natriuretic peptides cause lipolysis, a fact. that may be restoratively taken advantage of however that likewise calls for cautious portrayal of these impact.

Modulating the renin-angiotensin aldosterone pathway: innovative pathway

Renin-angiotensin-aldosterone system (RAAS) plays an important role in the human body.[33], but it also has an impact on the development of cardiovascular illnesses, such as hypertension and cardiovascular breakdown. The RAAS is constantly becoming more complex as research on angiotensin peptides, their additional receptors, and interplay with traditional angiotensin II receptors advances, as well as the establishment of the cerebrum renin-angiotensin framework (RAS). As a result, cross-controlled flagging groups might have a significant influence on controlling the sanctioned channel. Similarly, such organizations that activate the vasoprotective hub may contribute in the search for innovative drugs for the treatment of cardiovascular diseases. Old antihypertensive drugs include renin inhibitors, Pro inhibitors, and angiotensin II receptor blockers (stopping the movement of Ang1-7/Mas and Ang II-Ang type 1 receptor (AT1R)/Ang type-2 receptor (AT2R)), β-adrenoreceptor blockers (impeding the emission of renin), aldosterone-related blocker (obstructing the movement of the blend of aldosterone and receptor).[37]

Activators of the Angiotensin-Changing over Enzyme2/Angiotensin (1-7)/MAS Receptor Axis

The traditional renin-angiotensin framework (RAS) has been read up widely for a really long time furthermore, has yielded various effective treatments for hypertension and its intricacies. All the more as of late, parts of the RAS that play counter regulatory jobs have been recognized, portrayed and set forward as remedial focuses for hypertension and different types of CVD The carboxypeptidase angiotensin-changing over compound 2 (ACE2) changes over the decapeptide angiotensin I (Ang I) to the Ang (1-9) Nona peptide and the octapeptide Ang II to the Ang (1-7) heptapeptide. Ang (1-7) has been contemplated seriously and displayed to enact the G-protein-coupled Mas receptor, setting off a flagging outpouring that outcomes in vasodilation, decrease in oxidative pressure, and ant hypertrophic and ant fibrotic impacts.

The classical renin-angiotensin system (RAS) has been extensively studied for a long time, and it has provided several successful therapies for hypertension and related complexities. More recently, components of the RAS that perform counter regulatory roles have been recognized, depicted, and pushed forward as remedial focuses for hypertension and various forms of CVD. The carboxypeptidase angiotensin-converting enzyme 2 (ACE2) converts the decapeptide angiotensin I (Ang I) to the Ang (1-9) Nona peptide and the octapeptide Ang II to the Ang (1-7) heptapeptide. Ang (1-7) has been studied extensively and shown to activate the G-protein-coupled Mas receptor, resulting in vasodilation, a reduction in oxidative pressure, and antihypertrophic and antifibrotic effects.

The more recently described Ang (1-9) has been shown to reduce blood pressure and switch/enhance cardiovascular damage in animal models of hypertension by activating the angiotensin type 2 receptor.[38] In contrast to Ang 1-7, Ang 1-9 does not activate the Mas receptor. Preclinical studies are being conducted to determine the therapeutic potential of angiotensin type 2 receptor enactment. Compound 21 (C21), a particular non-peptide angiotensin type 2 receptor agonist, has been shown to have relaxing, anti-fibrotic, and anti-apoptotic characteristics while without lowering blood pressure. These findings suggest that C21 could be useful in preventing hypertension-induced target organ damage. Interest in ACE2 as a restorative target has motivated the development of small particle ACE2 activators, such XNT[39] and DIZE[40], which Reduce blood pressure, improve cardiac function,

and switch between myocardial and perivascular fibrosis in the immediately hypertensive mouse. Initiation of ACE2 also reduces monocrotaline-induced pneumonic hypertension via an instrument that incorporates Mas activation.[41] As an alternative to pharmaceutical ACE2 activation, recombinant human ACE2 (rhACE2) has been shown to lower blood pressure in SHR, to have calming effects in a model of lipopolysaccharide-induced lung damage, and to decrease the progression of diabetic nephropathy in animal models.

A stage I focus on in solid workers demonstrated sustained (>24 h) masking of circulating Ang II levels following a single intravenous infusion of rhACE2, with no influence on BP and no notable adverse effects.[42] Ang(1-7) has been regulated in stage I/II exams as a potential antiproliferative and antiangiogenic specialist for patients with cutting-edge malignant growths resistant to standard treatment, as well as a hematopoietic specialist for patients with multiline age cytopenias after chemotherapy.[43] These tests were limited in scope, and local Ang(1-7) has not been expanded further because to its short half-life in vivo. The combination of a cyclic Ang(1-7) and a hydroxypropyl-β-cyclodextrin-integrated Ang(1-7) has been shown to be Cardioprotective effects in animal models of cardiac dead tissue and insulin obstruction/type 2 diabetes.[44].

AngII-AT1R/ AT2R axis

Ang II functions primarily by initiating AT1Rs and AT2Rs. AT1Rs regulate vascular smooth muscle compression, aldosterone secretion, dipsogenic reactions, renal salt reabsorption, and pressor and tachycardia responses.[45] Alternatively, AT2Rs often cause the opposite effects, such as vasodilation, natriuretic, cell separation, and development inhibition.[46] As a result, AT2R agonists might be an effective therapy for hypertension. Compound 21 (C-21) is a highly selective nonpeptide AT2R agonist and the first detailed AT2R agonist.[47] AT2R activation induced a bradykinin-nitric oxide (NO)-cyclic guano sine 3,5-monophosphate (cGMP) flagging fountain that activated the downstream flagging arbiters Src kinase and extracellular sign related kinase, prompting the assimilation/inactivation of the major renal proximal tubule (RPT) Na+ carriers Na+/H+ exchanger 3 (NHE3) and Na+/K+ ATPase (NKA) and Inducing natriuresis.[48] Earlier studies discovered that Ang II can increase sodium maintenance and blood pressure in rats; however, the administration of C-21 prevented Ang II-induced sodium maintenance and blood pressure rise. The activation of continuous AT2R initiates and facilitates receptor translocation to RPT apical plasma films. It also promotes the assimilation/inactivation of NHE3 and NKA while inhibiting Na+ maintenance, resulting in a negative mixed Na+ equilibrium and lower BP in models of exploratory Ang II-induced hypertension. The findings indicated that C-21 is a promising medicine for the treatment of hypertension and Na+ holding states in humans. In a two-kidney, one-cut hypertensive rat model, C-21 significantly reduced TNF-α, IL-6, and TGF-β1 levels while increasing NO and cGMP levels. The kidneys.[49] These findings suggest that AT2R is another target for hypertension therapy, and AT2R agonists may serve as the primary antagonist of hypertensive drugs in the future.

Healthy Habits to Lower Blood Pressure

By way of life/change on a surface level (heaviness, high food intake of fat and salt, real latency, smoking, excessive alcohol use, poor dietary potassium consumption) to manage BP and to investigate the efficacy of pharmaceutical therapy for high blood pressure. To get the greatest benefits, nutrition, exercise, and other necessary adjustments should be initiated and discussed with the patient, and appropriate goals should be established, which should be reasonable. Self-drugging is a common sort of self-care that involves the use of products [such as over-the-counter (OTC) medicines, home-grown pharmaceuticals, nutritional supplements, and vitamins] to cure self-perceived health issues or diseases. It allows sufferers to presume. a sense of ownership in dealing with their well-being, resulting in a stronger identity. Not withstanding, self-medication methods can lead to medication collaborations due to the concurrent use of unprescribed goods and approved drugs[50], or they might create unintended consequences. People are focused on modifying their lives, which helps to maintain and regulate blood pressure.

Better diet for healthier heart

In terms of HTN prevention and treatment, recent dietary recommendations have focused on precise evidence analyzing food types consumed in combinations, or the overall dietary pattern, and the relationship between food and blood pressure. Overall, the Dietary Rules for Americans and the AHA/ACC/The Weight Society[51] have embraced a greater emphasis on dietary examples because they provide the opportunity to depict the overall wholesome thickness, and thus the dietary nature of something else'reasonable' eating habits in a population. Among the dietary examples considered, the Dietary Ways to Stop Hypertension (Run) diet has been consistently recommended by wellness associations (for example, Public Heart, Lung, and Blood Organization, AHA, Dietary standards for Americans, US (US) standards for treatment of high blood pressure) as a A beneficial diet for managing blood pressure. Early observational studies that found a link between low prevalence rates of HTN influenced its progress. Furthermore, CVD occurs in people who avoid consuming animal products and have low saturated fat, high polyunsaturated fat, and low cholesterol.[52] Sodium is the most essential factor contributing to high blood pressure. We can regulate our blood pressure by eating a low salt diet. The average American consumes around 3400 mg of salt per day, well beyond the top, safe limit of clinical dietary recommendations of 2400 mg/day.

Vaccine

The benefits envisaged from gene-based techniques may be equivalent to those provided by immunological approaches. Two hypertension vaccines have recently been developed: Cyt006 against Ang II and PMD3117 against Ang I. Even while there was considerable enthusiasm, the results were not favorable. Cyt006 lowered SHR BP, albeit at a lesser rate (9/4 mmHg)[52] than standard antihypertensives. In subsequent studies, Cyt006 failed to replicate this BP drop, despite shorter dose intervals and larger antibody titres, while PMD3117 did not lower BP, despite some amount of RAAS inhibition. Furthermore, to promote patient compliance, the proposed immunization regimens of Weeks 0, 4, 12, or 0, 2, 4, 6, and 10 may be insufficiently enticing. However, regardless of the Despite the fact that prior anti-renin vaccines were connected to severe renal disease, Cyt006 and PMD3117 were well tolerated in the Phase I research, and Cyt006 also reduced the rise in blood pressure in the early morning.

CONCLUSION

Finally, late advances in hypertension therapy have largely contributed to our ability to deal with this medical problem. This article examines new approaches such as drugs and therapy. A novel hypertension medicine may improve conventional therapies in a variety of ways. It has the ability to decrease blood pressure using a unique pharmacologic technique that allows for additional end-point reduction whether provided alone or in combination with other medications. Examples of such advances are the introduction of Expert inhibitors and beta-blockers. All progress and advancements in hypertension drugs and therapies help to lower blood pressure. However, because hypertension is a disease of daily living, we cannot fully cure it; all we can do is alter our lifestyle and diet.

REFERENCES

1. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta analysis. *Lancet*. **2016** 05;387(10022):957-967.
2. Armstrong C., Joint National Committee. JNC8 guidelines for the management of hypertension in adults. *Am Fam Physician*. **2014** 01;90(7):503 4.
3. Messerli FH, Bangalore S. Antihypertensive efficacy of aliskiren: *is hydrochlorothiazide an appropriate benchmark? Circulation*. **2009** 27;119(3):371-3.
4. United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, Key Findings and Advance Tables. Working Paper

No. ESA/P/WP.241United Nations (2015). *World Popu lation Prospects*: The **2015** 119(3):371-3

5. The prevalence of high blood pressure among U.S. adults by age and sex. *(Source: Heart Disease and Stroke Statistics*–**2020** Update: A report from the American Heart Association) 119(3):371-3.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Pro spective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi vidual data for one million adults in 61 prospective studies. *Lancet*. **2002**;14;360(9349):1903–13.
7. United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.241United Nations (2015*). World Popu lation Prospects*: The **2015.** 47, 20–33.
8. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat Rev Nephrol*. **2020**;16:223–37.
9. Muntner P, Carey RM, Giddiong S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK. Potential US population impact of the 2017 ACC/ AHA high blood pressure guideline. *Circulation*. **2018**;137:109–18.
10. Dzau,V.J.; Balatbat, C.A. Future of Hypertension. *Hypertension* **2019**, 74, 450–457.
11. DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry: New estimates of R&D *costs. J. Health Econ*. **2016**, 47, 20–33.
12. Hunter, P.G.; FChapman, A.; Dhaun, N. Hypertension: Current trends and future perspectives. *Br. J. Clin. Pharmacol***. 2021**, 87, 3721–3736.
13. Parati, G.; Stergiou, G.; O'Brien, E.; Asmar, R.; Beilin, L.; Bilo, G.; Clement, D.; de la Sierra, A.; de Leeuw, P.; Dolan, E.; et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J. *Hypertens*. **2014**, 32, 1359–1366.
14. Stergiou, G.S.; Palatini, P.; Parati, G.; O'Brien, E.; Januszewicz, A.; Lurbe, E.; Persu, A.; Mancia, G.; Kreutz, R.C.; European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. **2021** European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J. *Hypertens*. **2021**, 39, 1293–1302.
15. Koren, G.; Nordon, G.; Radinsky, K.; Shalev, V. Machine learning of big data in gaining insight into successful treatment of hypertension. *Pharmacol. Res. Perspect*. **2018**, 6, e00396.
16. Madhurantakam, S.; Babu, K.J.; Rayappan, J.B.B.; Krishnan, U.M. Nanotechnology-based electrochemical detection strategies for hypertension markers. *Biosens. Bioelectron*. **2018**, 116, 67–80.
17. Park, S.H.; Zhang, Y.; Rogers, J.A.; Gallon, L. Recent advances of biosensors for hypertension and nephrology. Curr. Opin. Nephrol. *Hypertens*. **2019**, 28, 390–396.
18. Farhadi F, Aliyari R, Ebrahimi H, Hashemi H, Emamian MH, Fotouhi A. Prevalence of uncontrolled hypertension and its associated factors in 50–74 years old Iranian adults: a population based study. *BMC Cardiovasc Disord* **2023**;23:318.
19. Carey RM, Wright JT, Taler SJ, Whelton PK. Guideline-driven management of hypertension. *Circ Res* **2021**;128:827-46.
20. Antonakoudis G, Poulimenos L, Kifnidis K, Zouras C, Antonakoudis H. Blood pressure control and cardiovascular risk reduction. *Hippokratia* **2007**;11:114-9.
21. Yaxley JP, Thambar SV. Resistant hypertension: an approach to management in primary care. *J Fam Med Prim Care* **2015**;4:193-9.
22. Dhillon S. Aprocitentan: first approval. Drugs. doi:**2021**, 10.1007/s40265 024-02053-0.
23. Freeman BD, Machado FS, Tanowitz HB, Desruisseaux MS. Endothelin-1 and its role in the pathogenesis of infectious diseases. *Life Sci* **2014**;118:110-9.
24. US FDA. FDA label for Aprocitentan. 2024. Available from: *https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/ 217686s000lbl.pdf* **2024** .
25. Balavoine, F., Azizi, M., Blanchard, A., et al. "Firibastat, a First-in-Class Brain Aminopeptidase A Inhibitor, for the Treatment of Hypertension in Patients of Black African Ancestry: Results of

the Phase IIb NEW-HOPE Study." *Circulation*, 140(15),**2019** 1289–1297. doi:10.1161/CIRCULATIONAHA.119.041062.
26. Azizi, M., Rossignol, P., and Girerd, X. "Aminopeptidase A inhibitors: a new strategy for the treatment of hypertension." *Journal of Hypertension*, **2020** 38(5), 911–917. doi:10.1097/HJH.0000000000002356.
27. Khosla J, Aronow WS, Frishman WH. Firibastat: an oral first-in-class brain aminopeptidase A inhibitor for systemic hypertension. *Cardiology in Review*. **2022** 1;30(1):50-5.
28. Khosla, Jagjit, Wilbert S. Aronow, and William H. Frishman. "Firibastat: an oral first-in-class brain aminopeptidase A inhibitor for systemic hypertension." *Cardiology in Review* 30, no. 1 **2022**: 50-55.
29. Gras J. Firibastat. Brain aminopeptidase A inhibitor, Treatment of difficult-to-treat or resistant hypertension, Treatment of heart failure. *Drugs of the Future*. **2022** 1;46(2).
30. Saha SK, Moni TT, Kadir MR. The Long-Term Effects of Olmesartan Combined Amlodipine among Hypertensive Patients in a Tertiary Care Hospital–A Retrospective Study. Saudi J Med. **2024**;9(2):41-7.
31. Anker, S. D., Butler, J., Filippatos, G., et al.. "Vericiguat in patients with heart failure with reduced ejection fraction after worsening heart failure: a randomised, parallel-group, placebo-controlled, double-blind, event-driven trial." *Lancet*, 397(10271), **2021**,154-164.
32. Armstrong, P. W., Pieske, B., Anstrom, K. J., et al. "Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction." *The New England Journal of Medicine*, 382(20), **2021:**1883-1893.
33. Intengan HD, Schiffrin EL. "Vasopeptidases inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats." *Hypertension* **2000**; 35:1221–1225.
34. Tabrizchi R. Omapatrilat. Bristol-Myers Squibb. "Current opinion in investigational drugs (*London, England: 2000*)." **2001** 1; 2(10):1414-22.
35. Ruilope LM, Dukat A, Bo¨hm M, Lacourcie`re Y, Gong J, Lefkowitz MP. "Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and Neprilysin: a randomised, double-blind, placebo-controlled, active comparator study." *Lancet* **2010**; 375:1255–1266.
36. Gao Q, Xu L, and Cai J. "New drug targets for hypertension: A literature review." *Biochemical ET Biophysical Act: Molecular Basis of Disease*. **2021**; 1867(3):166037-166037.
37. Ocaranza MP, Moya J, Barrientos V, et al. "Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis." *J hypertension.* **2014**; 32:771– 783.
38. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, Raizada MK. "Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases." *Exp Physiol.* **2011**; 96:287–294.
39. Kulemina LV, Ostrov DA. "Prediction of off-target effects on angiotensin-converting enzyme 2." *J Biomol Screen.* **2011**; 16:878–885.
40. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellanos RK, Ostrov DA, Oh SP, Katovich MJ, Raizada MK. "Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension." *Am J Respire Crit Care Med.* **2009**; 179:1048–1054.
41. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzburg M, Bruggisser M, Penninger J, Krähenbühl S. "Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects." *Clin Pharmacokinetic.* **2013**; 52:783–792.
42. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. "Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone." *Clin Cancer Res.* **2009**; 15:7398–7404.
43. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN, Haas M. "Angiotensin-(1-7) with together bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analogy." *J Pharmacol Exp Ther.* **2009**; 328:849–854.

44. R.M. Carey, H.M. Siragy," Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation, *Endocr*." Rev.**2003**; 261–271.
45. B.A. Kemp, N.L. Howell, S.R. Keller, J.J. Gildea, S.H. Padia, R.M. Carey, "AT2 receptor activation prevents sodium retention and reduces blood pressure in angiotensin II-dependent hypertension." *Circ. Res.* 119:**2016**; 532–543.
46. Y. Wan, C. Wallinder, B. Plouffe, H. Beaudry, A.K. Maralinga, X. Wu, et al., "Design, synthesis, and biological evaluation of the first selective non peptide AT2 receptor agonist." *J. Med. Chem.* 47:**2004**; 5995–6008.
47. B.A. Kemp, N.L. Howell, J.J. Gildea, S.R. Keller, S.H. Padia, R.M. Carey, "AT2 receptor activation induces natriuretic and lowers blood pressure." *Circ. Res.* 115:**2014**; 388–399.
48. L.C. Matavelli, J. Huang, H.M. Siragy, "Angiotensin AT2 receptor stimulation inhibits early renal inflammation in Reno vascular hypertension." *Hypertension* 57:**2011**; 308–313.
49. Qato DM, Alexander GC, Conti RM, et al. "Use of prescription and over the-counter medications and dietary supplements among older adults in the United States." *JAMA* **2008**; 300: 2867–78.
50. Jensen MD, Ryan DH, Apovian CM, et al. 2013 "AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society." *J Am Coll Cardiol* **2014**; 63(25 Pt. B):2985–3023.
51. Sacks FM, Rosner B, Kass EH. "Blood pressure in vegetarians." *Am J Epidemiology* **1974**; 100:390–398
52. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. "Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects." *Clin Sci (Lond)* **2004**; 107: 167–173.